Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Jonathan D. Schoenfeld, MD, MPhil, MPH


Radiation Oncology

Make an Appointment

Physician

  • Director, Melanoma Radiation Oncology
  • Senior Physician
  • Associate Professor of Radiation Oncology, Harvard Medical School

Clinical Interests

  • Head and neck cancers
  • Melanoma
  • Skin cancer
  • Tumor immunology

Contact Information

  • Appointments617-632-5296
  • Office Phone Number617-632-5296
  • Fax617-394-2667

Bio

Dr. Schoenfeld is a radiation oncologist in the head and neck and melanoma disease centers, a member of the Cancer Immunology program in the Dana-Farber/Harvard Cancer Center, and Assistant Professor of Radiation Oncology at Harvard Medical School.  He received his medical degree from Harvard Medical School after completing a research fellowship at the University of Cambridge in the UK as a Gates Fellow. He performed his medical internship at Memorial Sloan Kettering Cancer Center, then completed residency in radiation oncology in the Harvard Radiation Program and received a Master of Public Health in Clinical Effectiveness from the Harvard T.H. Chan School of Public Health.  His research focuses on the design and implementation of clinical, epidemiologic and translational studies in head and neck and skin cancers.  He is actively evaluating the immunologic effects of radiation therapy and exploring treatments combining radiation with novel immune oncology agents. 

Fellowship:

  • Harvard School of Public Health
  • University of Cambridge, UK

Residency:

  • Harvard Radiation Program, Radiation Oncology

Medical School:

  • Harvard Medical School

Research

Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. J Immunother. 2021 Oct 01; 44(8):307-318.
View in: PubMed

Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2021 Sep 01; 27(17):4940.
View in: PubMed

Prospective clinical investigation of the efficacy of combination radiotherapy with immune checkpoint inhibition. Int J Radiat Oncol Biol Phys. 2021 Aug 16.
View in: PubMed

Personalized Radiation Attenuating Materials for Gastrointestinal Mucosal Protection. Adv Sci (Weinh). 2021 06; 8(12):2100510.
View in: PubMed

Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose? J Immunother Cancer. 2021 Apr; 9(4).
View in: PubMed

A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2021 May 01; 27(9):2470-2480.
View in: PubMed

The effects of releasing early results from ongoing clinical trials. Nat Commun. 2021 02 05; 12(1):801.
View in: PubMed

Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges. Front Oncol. 2020; 10:608772.
View in: PubMed

Clinical Decision-making About Neoadjuvant Nivolumab Plus Ipilimumab-Reply. JAMA Oncol. 2021 Feb 01; 7(2):309-310.
View in: PubMed

Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clin Cancer Res. 2021 Jan 01; 27(1):357.
View in: PubMed

Reply to "Keynote 48: Is it really for everyone?" Oral Oncol. 2021 04; 115:105108.
View in: PubMed

Head and Neck Cancer Clinical Research on ClinicalTrials.gov: An Opportunity for Radiation Oncologists. Adv Radiat Oncol. 2021 May-Jun; 6(3):100608.
View in: PubMed

Association between treatment center experience and survival after diagnosis of stage I to III Merkel cell carcinoma treated with surgery with or without postoperative radiation therapy. J Am Acad Dermatol. 2021 Mar; 84(3):875-877.
View in: PubMed

Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. Oral Oncol. 2021 01; 112:105087.
View in: PubMed

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1563-1570.
View in: PubMed

Radiation-Induced Hypothyroidism in Patients with Oropharyngeal Cancer Treated with IMRT: Independent and External Validation of Five Normal Tissue Complication Probability Models. Cancers (Basel). 2020 Sep 22; 12(9).
View in: PubMed

Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases. Cancer. 2020 12 15; 126(24):5274-5282.
View in: PubMed

Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin. Head Neck. 2020 12; 42(12):3670-3677.
View in: PubMed

A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):134-144.
View in: PubMed

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clin Cancer Res. 2020 10 01; 26(19):5140-5152.
View in: PubMed

Keynote 48: Is it really for everyone? Oral Oncol. 2020 06; 105:104762.
View in: PubMed

Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy. World Neurosurg. 2020 07; 139:226-231.
View in: PubMed

The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. Oncologist. 2020 07; 25(7):598-608.
View in: PubMed

Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. Oral Oncol. 2020 07; 106:104690.
View in: PubMed

Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2020 06; 105:104676.
View in: PubMed

A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. Clin Breast Cancer. 2020 06; 20(3):238-245.
View in: PubMed

Short-term mortality risks among patients with oropharynx cancer by human papillomavirus status. Cancer. 2020 04 01; 126(7):1424-1433.
View in: PubMed

Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series. Oral Dis. 2020 Mar; 26(2):325-333.
View in: PubMed

Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. J Clin Oncol. 2020 01 20; 38(3):214-222.
View in: PubMed

Immunotherapy and Radiation: Charting a Path Forward Together. Hematol Oncol Clin North Am. 2019 12; 33(6):1057-1069.
View in: PubMed

Lessons Learned from Deescalation Trials in Favorable Risk HPV-Associated Squamous Cell Head and Neck Cancer-A Perspective on Future Trial Designs. Clin Cancer Res. 2019 12 15; 25(24):7281-7286.
View in: PubMed

PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer. Transl Lung Cancer Res. 2019 Sep; 8(Suppl 2):S139-S146.
View in: PubMed

Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2019 10; 28(10):1660-1667.
View in: PubMed

A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):132-139.
View in: PubMed

Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. J Immunother Cancer. 2019 04 24; 7(1):112.
View in: PubMed

Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy. Front Oncol. 2019; 9:199.
View in: PubMed

Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J Immunother Cancer. 2019 03 29; 7(1):89.
View in: PubMed

Everolimus in Anaplastic Thyroid Cancer: A Case Series. Front Oncol. 2019; 9:106.
View in: PubMed

Outcomes following radiation for cutaneous squamous cell carcinoma of the head and neck: Associations between immune suppression and recurrence. Head Neck. 2019 07; 41(7):2111-2115.
View in: PubMed

Radiation Therapy and Immune Modulation. Hematol Oncol Clin North Am. 2019 04; 33(2):233-248.
View in: PubMed

IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. Head Neck. 2019 04; 41(4):959-966.
View in: PubMed

Denaturation-Enhanced Droplet Digital PCR for Liquid Biopsies. Clin Chem. 2018 12; 64(12):1762-1771.
View in: PubMed

The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys. 2019 01 01; 103(1):142-151.
View in: PubMed

We Are All Connected: Modeling the Tumor-Immune Ecosystem. Trends Cancer. 2018 10; 4(10):655-657.
View in: PubMed

Immunotherapy and radiotherapy for metastatic cancers. Ann Palliat Med. 2019 Jul; 8(3):312-325.
View in: PubMed

Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. Oral Oncol. 2018 10; 85:29-34.
View in: PubMed

Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation. JAMA Oncol. 2018 08 01; 4(8):1123-1124.
View in: PubMed

Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):137-145.
View in: PubMed

Funding Support and Principal Investigator Leadership of Oncology Clinical Trials Using Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):34-43.
View in: PubMed

Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. Int J Radiat Oncol Biol Phys. 2018 08 01; 101(5):1259-1270.
View in: PubMed

Hazards of Hazard Ratios - Deviations from Model Assumptions in Immunotherapy. N Engl J Med. 2018 03 22; 378(12):1158-1159.
View in: PubMed

Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018 02 22; 3(4).
View in: PubMed

Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018 05; 18(5):313-322.
View in: PubMed

Potential Role of the Quality Assurance Review Center Platform in Global Radiation Oncology. Int J Radiat Oncol Biol Phys. 2017 11 15; 99(4):956-962.
View in: PubMed

The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 11; 22(11):1413.
View in: PubMed

Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. Oral Oncol. 2017 10; 73:160-165.
View in: PubMed

Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. Front Oncol. 2017; 7:191.
View in: PubMed

Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiother Oncol. 2017 07; 124(1):98-103.
View in: PubMed

Evaluating the potential for maximized T cell redistribution entropy to improve abscopal responses to radiotherapy. Converg Sci Phys Oncol. 2017 Sep; 3(3).
View in: PubMed

Prospective analysis of radiation oncology image and plan-driven peer review for head and neck cancer. Head Neck. 2017 08; 39(8):1603-1608.
View in: PubMed

The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 03; 22(3):343-350.
View in: PubMed

Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2017 04; 67:61-69.
View in: PubMed

Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):344-351.
View in: PubMed

Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomark. 2017; 19(2):129-136.
View in: PubMed

Merkel Cell Carcinoma: A Population Analysis on Survival. J Natl Compr Canc Netw. 2016 10; 14(10):1247-1257.
View in: PubMed

Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. Oral Oncol. 2016 10; 61:19-26.
View in: PubMed

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer. 2016 07 12; 115(2):252-60.
View in: PubMed

Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. J Immunother Cancer. 2016; 4:32.
View in: PubMed

Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunol Res. 2016 08; 4(8):679-87.
View in: PubMed

The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With Radiation. Am J Clin Oncol. 2016 06; 39(3):243-7.
View in: PubMed

Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer. Head Neck. 2016 10; 38(10):1530-8.
View in: PubMed

Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment. Prostate Cancer Prostatic Dis. 2016 06; 19(2):197-201.
View in: PubMed

Synchronous squamous cell carcinoma and diffuse large B-cell lymphoma of the head and neck: the odd couple. BJR Case Rep. 2016; 2(1):20150271.
View in: PubMed

Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2016 06 15; 22(12):2939-49.
View in: PubMed

Radiation dose and checkpoint blockade immunotherapy: unanswered questions. Lancet Oncol. 2016 Jan; 17(1):e3-4.
View in: PubMed

Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer. 2015; 3:50.
View in: PubMed

Radiation Oncology--New Approaches in Squamous Cell Cancer of the Head and Neck. Hematol Oncol Clin North Am. 2015 Dec; 29(6):1093-106.
View in: PubMed

A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015 Nov; 4(11):e1046028.
View in: PubMed

Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era. Cancer. 2015 Aug 01; 121(15):2594-602.
View in: PubMed

Immune effects of targeted radiation therapy for cancer. Discov Med. 2015 Mar; 19(104):219-28.
View in: PubMed

Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Oncol Pract. 2015 Mar; 11(2):151-4.
View in: PubMed

Immunity in head and neck cancer. Cancer Immunol Res. 2015 Jan; 3(1):12-7.
View in: PubMed

Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Clin Oncol. 2014 Oct 20; 32(30_suppl):100.
View in: PubMed

Reply to 'Meta-analysis procedure for the effect of statin on the recurrence of prostate cancer' by T. Kawada. Ann Oncol. 2014 Feb; 25(2):543-4.
View in: PubMed

Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Ann Oncol. 2013 Jun; 24(6):1427-34.
View in: PubMed

A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. Clin Cancer Res. 2013 Mar 15; 19(6):1612-9.
View in: PubMed

Is everything we eat associated with cancer? A systematic cookbook review. Am J Clin Nutr. 2013 Jan; 97(1):127-34.
View in: PubMed

PET/CT of cancer patients: part 2, deformable registration imaging before and after chemotherapy for radiation treatment planning in head and neck cancer. AJR Am J Roentgenol. 2012 Nov; 199(5):968-74.
View in: PubMed

Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib--a case report. Anticancer Res. 2012 May; 32(5):1743-6.
View in: PubMed

Lung malignancies after Hodgkin lymphoma: disease characteristics, detection methods and clinical outcome. Ann Oncol. 2012 Jul; 23(7):1813-8.
View in: PubMed

Abbreviated course of radiotherapy (RT) for breast cancer. Breast. 2011 Oct; 20 Suppl 3:S116-27.
View in: PubMed

Anti-angiogenesis immunotherapy. Hum Vaccin. 2011 Sep; 7(9):976-81.
View in: PubMed

Colorectal cancer in African American and Caucasian patients: A comparison of an urban, university hospital with the National Cancer Institute SEER database. J Clin Oncol. 2011 May 20; 29(15_suppl):3631.
View in: PubMed

Gastric adenocarcinoma treated with radiation with or without epirubicin-based chemotherapy: Evaluation of radiation-induced liver disease. J Clin Oncol. 2011 Feb; 29(4_suppl):110.
View in: PubMed

Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 2010 Dec 15; 70(24):10150-60.
View in: PubMed

Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):308-14.
View in: PubMed

PECAM-1 affects GSK-3beta-mediated beta-catenin phosphorylation and degradation. Am J Pathol. 2006 Jul; 169(1):314-24.
View in: PubMed

Identification of the regions of PECAM-1 involved in beta- and gamma-catenin associations. Biochem Biophys Res Commun. 2005 Apr 22; 329(4):1225-33.
View in: PubMed

Bioinformatic analysis of primary endothelial cell gene array data illustrated by the analysis of transcriptome changes in endothelial cells exposed to VEGF-A and PlGF. Angiogenesis. 2004; 7(2):143-56.
View in: PubMed

PECAM-1 promotes beta-catenin accumulation and stimulates endothelial cell proliferation. Biochem Biophys Res Commun. 2003 Mar 28; 303(1):212-8.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Brigham and Women's Hospital
75 Francis Street
Boston, MA 02215
Get Directions

Ratings

Top